On July 21, 2021, a group of state attorneys general proposed a $26 billion settlement proposal to resolve claims that McKesson Corp., Cardinal Health, Inc., AmerisourceBergen Corp., and Johnson & Johnson (“J&J,” and together with McKesson Corp., Cardinal Health, Inc., and AmerisourceBergen Corp., the “Settling Parties”) contributed to the opioid epidemic in the United States.
Latest Post
More Posts
Invidior Pays $300M to Settle Claims that it Improperly Marketed Suboxone
Cornerstone Research 2020 Report Identifies Trends In Securities Litigation Filings Affecting Life Sciences Firms
Year-End NERA Report Shows COVID-19-Related Federal Securities Litigation Disproportionately Targeting Life Sciences Firms
S.D.N.Y. Rejects Proposed Amended Complaint Alleging Manufacturer Of Liver Disease Drug Intended To Commit Fraud By Not Disclosing Serious Adverse Events
Mid-Year NERA Report Shows COVID-19-Related Federal Securities Litigation Targeting Pharmaceutical Industry
S.D.N.Y. Preliminarily Approves $1.6 Million Settlement in Class Action Concerning Development of an OxyContin Alternative
First Circuit Affirms Dismissal of Action Regarding Statements Concerning Manufacturing of Eye Drug
Cornerstone Research Report Shows Continued Rate of Federal Securities Litigation Filings Targeting Pharmaceutical Industry
District Court Judge Partially Dismisses Claims Against Celgene, But Allows Allegations Regarding Misleading Statements About Sales Projections and FDA Approval to Proceed
Subscribe: Subscribe via RSS
Firm/Org